Home>>Signaling Pathways>> Proteases>> Endogenous Metabolite>>Acetylcysteine

Acetylcysteine (Synonyms: N-acetylcysteine; N-acetyl-L-cysteine; NAC; Acetadote)

Catalog No.GC11786

Acetylcysteine is the N-acetyl derivative of CYSTEINE.

Products are for research use only. Not for human use. We do not sell to patients.

Acetylcysteine Chemical Structure

Cas No.: 616-91-1

Size Price Stock Qty
5g
$38.00
In stock
10g
$42.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 4 publications

Product Documents

Quality Control & SDS

View current batch:

Protocol

Kinase experiment [1]:

Preparation Method

PRP was preincubated at 37°C for 4 min with Acetylcysteine or with nitroglycerin, or first with Acetylcysteine and then nitroglycerin, and sodium nitroprusside, sodium azide, sodium nitrite, or S-nitroso-N-acetylcysteine for 1 min before addition of agonist.

Reaction Conditions

5.5 mM Acetylcysteine for 4 min

Applications

Millimolar concentrations of Acetylcysteine potentiated markedly the inhibitory effect of nitroglycerin on platelet aggregation induced by ADP, epinephrine, collagen, and arachidonate, decreasing the 50% inhibitory concentration (IC50) approximately 50-fold for each of these agents.

Cell experiment [2]:

Cell lines

PC12 cell line

Preparation Method

Cells were treated with 100 ng/ml NGF or 60 mm Acetylcysteine in serum-containing medium for the indicated times.

Reaction Conditions

60 mm Acetylcysteine for 15min-4h

Applications

Acetylcysteine activates the Ras-ERK pathway

Animal experiment [3]:

Animal models

Thirty-five male Wistar rats

Preparation Method

Group control underwent IIR without Acetylcysteine. In the other groups, Acetylcysteine was administered intraperitoneally with different regimens: 150 mg/kg before ischemia, 300 mg/kg before ischemia, and 150 mg/kg before ischemia plus 150 mg/kg 5 min before reperfusion.

Dosage form

150-300 mg/kg Acetylcysteine(Intraperitoneal administration)

Applications

Acetylcysteine exerts a significant protective role in liver injury following IIR, which seems to be independent of an intestinal protective effect. Additional administration of Acetylcysteine before reperfusion was of no further benefit. The most effective regimen among the compared regimens was that of 300 mg/kg before ischemia.

References:

[1]. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985 Aug;76(2):703-8. doi: 10.1172/JCI112024. PMID: 2863286; PMCID: PMC423881.

[2]. Yan CY, Greene LA. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J Neurosci. 1998 Jun 1;18(11):4042-9. doi: 10.1523/JNEUROSCI.18-11-04042.1998. PMID: 9592085; PMCID: PMC6792807.

[3]. Kalimeris K, Briassoulis P, et,al. N-acetylcysteine ameliorates liver injury in a rat model of intestinal ischemia reperfusion. J Surg Res. 2016 Dec;206(2):263-272. doi: 10.1016/j.jss.2016.08.049. Epub 2016 Aug 19. PMID: 27884318.

Background

Acetylcysteine is the N-acetyl derivative of CYSTEINE. NAC (N-acetyl-L-cysteine) is commonly used to identify and test ROS (reactive oxygen species) inducers, and to inhibit ROS.Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus[1]. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. Acetylcysteine also has anti-influenza virus activities[5].

Millimolar concentrations of Acetylcysteine potentiated markedly the inhibitory effect of nitroglycerin on platelet aggregation induced by ADP, epinephrine, collagen, and arachidonate, decreasing the 50% inhibitory concentration (IC50) approximately 50-fold for each of these agents.In the absence of Acetylcysteine, nitroglycerin induced a marked decrease in platelet-reduced glutathione content as S-nitroso-thiol adducts were produced. The synthetic S-nitroso-thiol, S-nitroso-N-acetylcysteine, markedly inhibited platelet aggregation with an IC50 of 6 nM[7].Acetylcysteine increased ERK-1 activity in PC12 cells after 15 min of treatment and maximal stimulatory activity for 60 min. We also observed that Acetylcysteine caused tyrosine phosphorylation of ERK-1 in cells treated with this compound for 30 min[4].Acetylcysteine induces cell apoptosis. When used serum-deprived PC12 cells, neuronally differentiated PC12 cells deprived of serum and NGF, and NGF-deprived neonatal sympathetic neurons. In each case L-Acetylcysteine prevents apoptotic DNA fragmentation and maintains long-term survival in the absence of other trophic support[3].Acetylcysteine prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[2].

In mice, Acetylcysteine exerts a significant protective role in liver injury following IIR, which seems to be independent of an intestinal protective effect. Additional administration of Acetylcysteine before reperfusion was of no further benefit. The most effective regimen among the compared regimens was that of 300 mg/kg before ischemia[6].

References:
[1]: Halasi M, Wang M, et,al. ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. Biochem J. 2013 Sep 1;454(2):201-8. doi: 10.1042/BJ20130282. PMID: 23772801; PMCID: PMC4322432.
[2]: Farr SA, Poon HF, et,al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003 Mar;84(5):1173-83. doi: 10.1046/j.1471-4159.2003.01580.x. PMID: 12603840.
[3]: Ferrari G, Yan CY, et,al. N-acetylcysteine (D-and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci. 1995 Apr;15(4):2857-66. doi: 10.1523/JNEUROSCI.15-04-02857.1995. PMID: 7722634; PMCID: PMC6577755.
[4]: Yan CY, Greene LA. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J Neurosci. 1998 Jun 1;18(11):4042-9. doi: 10.1523/JNEUROSCI.18-11-04042.1998. PMID: 9592085; PMCID: PMC6792807.
[5]: Garigliany MM, Desmecht DJ. N-acetylcysteine lacks universal inhibitory activity against influenza A viruses. J Negat Results Biomed. 2011 May 9;10:5. doi: 10.1186/1477-5751-10-5. PMID: 21554703; PMCID: PMC3104374.
[6]: Kalimeris K, Briassoulis P, et,al. N-acetylcysteine ameliorates liver injury in a rat model of intestinal ischemia reperfusion. J Surg Res. 2016 Dec;206(2):263-272. doi: 10.1016/j.jss.2016.08.049. Epub 2016 Aug 19. PMID: 27884318.
[7]: Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985 Aug;76(2):703-8. doi: 10.1172/JCI112024. PMID: 2863286; PMCID: PMC423881.

Chemical Properties

Cas No. 616-91-1 SDF
Synonyms N-acetylcysteine; N-acetyl-L-cysteine; NAC; Acetadote
Chemical Name (2R)-2-acetamido-3-sulfanylpropanoic acid
Canonical SMILES CC(=O)NC(CS)C(=O)O
Formula C5H9NO3S M.Wt 163.19
Solubility DMF: 50 mg/mL,DMSO: 50 mg/mL,Ethanol: 50 mg/mL,PBS (pH 7.2): 30 mg/mL Storage 4°C, protect from light
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 6.1278 mL 30.6391 mL 61.2783 mL
5 mM 1.2256 mL 6.1278 mL 12.2557 mL
10 mM 0.6128 mL 3.0639 mL 6.1278 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Related Video

    Acetylcysteine-GlpBio

Reviews

Review for Acetylcysteine

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Acetylcysteine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.